Kintegral Advisory LLC Sells 3,101 Shares of CVS Health Co. (NYSE:CVS)

Kintegral Advisory LLC lessened its stake in CVS Health Co. (NYSE:CVS) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,581 shares of the pharmacy operator’s stock after selling 3,101 shares during the period. Kintegral Advisory LLC’s holdings in CVS Health were worth $2,989,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CVS. MidAtlantic Capital Management Inc. acquired a new position in shares of CVS Health during the third quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in CVS Health during the 3rd quarter valued at about $31,000. Reston Wealth Management LLC bought a new position in shares of CVS Health in the 3rd quarter valued at about $32,000. Ridgewood Investments LLC grew its position in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 450 shares during the period. Finally, Stonebridge Financial Group LLC bought a new stake in shares of CVS Health during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CVS. Cantor Fitzgerald upgraded shares of CVS Health from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 12th. Wolfe Research upped their price objective on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Truist Financial raised their target price on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Barclays upped their price target on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research note on Tuesday. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.

CVS Health Price Performance

CVS stock opened at $63.42 on Friday. The stock has a market cap of $79.95 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 0.98 and a beta of 0.61. The stock has a 50-day moving average price of $52.39 and a two-hundred day moving average price of $56.23. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $80.75. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 4.19%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 72.68%.

Insider Buying and Selling at CVS Health

In related news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.24% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.